Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-37732
Titel: | New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade : Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide |
VerfasserIn: | Rosar, Florian Dewes, Sebastian Ries, Martin Schaefer, Andrea Khreish, Fadi Maus, Stephan Bohnenberger, Hendrik Linxweiler, Johannes Bartholomä, Mark Ohlmann, Carsten Ezziddin, Samer |
Sprache: | Englisch |
Titel: | European Journal of Nuclear Medicine and Molecular Imaging |
Bandnummer: | 47 |
Heft: | 3 |
Seiten: | 687-694 |
Verlag/Plattform: | Springer Nature |
Erscheinungsjahr: | 2020 |
Freie Schlagwörter: | Metastatic castration-resistant prostate cancer PSMA radioligand therapy Androgen deprivation therapy Enzalutamide Upregulation of PSMA expression |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Purpose There is preliminary evidence for prostate-specific membrane antigen (PSMA) upregulation effects of androgen receptor blockade in prostate cancer. In an attempt to find the best condition for PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment. Methods Ten patients with advanced mCRPC scheduled for PSMA radioligand therapy were examined with 68Ga-PSMA-11 PET/CT before and after a mean of 11.8 days of enzalutamide 160 mg/day. Imaging results were compared using total PSMA tumor burden quantification. We assessed whole-body total lesion PSMA (TLP), defined as SUVmean × tumor volume and calculated TLP-to-liver ratio (TLP-LR), TLP-to-parotid gland ratio (TLP-PR), and TLP-to-kidney ratio (TLP-KR). Results The mean (median) increase of TLP-LR, TLP-PR, and TLP-KR in the cohort was 49.3% (38.8%), 45.1% (23.5%), and 54.9% (37.6%), respectively. These increases were statistically significant (p = 0.002, p = 0.014, and p = 0.014), while PSA values did not change significantly (p = 0.846). Seven of the 10 patients had previously undergone enzalutamide treatment with eventual progression, formally classified as treatment failure. No side effects were noted in the short term. Conclusions Our results suggest that enzalutamide could be considered as a PSMA radioligand treatment enhancing primer medication, which may increase PSMA expression by a dimension of 50% in mCRPC. The effect was shown even in patients having previously failed enzalutamide treatment for arrest of progression in the mCRPC setting. Our observation deserves evaluation in a prospective setting. |
DOI der Erstveröffentlichung: | 10.1007/s00259-019-04674-0 |
URL der Erstveröffentlichung: | https://link.springer.com/article/10.1007/s00259-019-04674-0 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-377326 hdl:20.500.11880/34122 http://dx.doi.org/10.22028/D291-37732 |
ISSN: | 1619-7089 1619-7070 |
Datum des Eintrags: | 26-Okt-2022 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Radiologie M - Urologie und Kinderurologie |
Professur: | M - Prof. Dr. Samer Ezziddin M - Prof. Dr. Michael Stöckle |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.